Defining the Morbidity of Robot-Assisted Radical Cystectomy with Intracorporeal Urinary Diversion: Adoption of the Comprehensive Complication Index.

Journal: Journal of endourology
Published Date:

Abstract

The Clavien-Dindo Classification (CDC) only reports the postoperative complication of highest grade. It is thus of limited value for radical cystectomy, after which patients usually experience multiple complications. The Comprehensive Complication Index (CCI) is a novel scoring system, which incorporates all postoperative events in one single value. The study aimed to adopt the CCI for the evaluation of complications in patients undergoing robot-assisted radical cystectomy (RARC) with intracorporeal urinary diversion (ICUD) and explore its advantages in the analysis of the morbidity of RARC with ICUD. A multicentric cohort of 959 patients undergoing RARC+ICUD between 2015 and 2020, whose complications are encoded in local prospective registries. Postoperative complications at 30 days were assessed using both the CDC and CCI. The CCI was calculated using an online tool (assessurgery.com). Risk factors for overall, major complications (CDC ≥III), and CCI were evaluated using uni- and multivariable logistic and linear regressions. To analyze the potential advantage of using the CCI in clinical trials, a sample size calculation of a hypothetic clinical trial was performed using as endpoint reduction of morbidity with either the CDC or CCI. Overall, 885 postoperative complications were reported in 507 patients (53%). The CCI improved the definition of postoperative morbidity in 22.6% of patients. Male sex and neobladder were associated with major complications and to a significant increase in CCI on adjusted regressions. In a hypothetical clinical trial, 80 patients would be needed to demonstrate a ten-point reduction in CCI, compared with 186 needed to demonstrate an absolute risk reduction of 20% in overall morbidity using the CDC. CCI improves the evaluation of postoperative morbidity by considering the cumulative aspect of complications compared with the CDC. Implementing the CCI for radical cystectomy would help reducing sample sizes in clinical trials. Clinical Trial Registration number: NCT03049410.

Authors

  • Simone Albisinni
    Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
  • Romain Diamand
    Department of Urology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
  • Georges Mjaess
    Department of Urology, Hotel Dieu de France, Beirut, Lebanon.
  • Fouad Aoun
    Department of Urology, Hotel Dieu de France, Beirut, Lebanon.
  • Gregoire Assenmacher
    Department of Urology, Cliniques de l'Europe-Saint Elisabeth, Brussels, Belgium.
  • Christophe Assenmacher
    Department of Urology, Cliniques de l'Europe-Saint Elisabeth, Brussels, Belgium.
  • Grégory Verhoest
    Department of Urology, Rennes University Hospital, 2, rue Henri Le Guilloux, 35033, Rennes Cedex, France.
  • Serge Holz
    Department of Urology, CHU Ambroise Paré, Mons, Belgium.
  • Michel Naudin
    Department of Urology, CHU Ambroise Paré, Mons, Belgium.
  • Guillaume Ploussard
    Department of Urology, La Croix du Sud Hospital, Quint Fonsegrives, France.
  • Andrea Mari
  • Andrea Minervini
    Department of Urology, Careggi Hospital, University of Florence, Florence, Italy.
  • Andrea Tay
    Department of Urology, Saint Georges Hospital, London, United Kingdom.
  • Rami Issa
    Department of Urology, Saint Georges Hospital, London, United Kingdom.
  • Mathieu Roumiguié
    Department of Urology, University of Toulouse, Toulouse, France.
  • Anne Sophie Bajeot
    Department of Urology, Andrology, and Renal Transplantation, CHU Rangueil, Paul-Sabatier University, Toulouse Cedex, France.
  • Giuseppe Simone
    Department of Urology, Regina Elena National Cancer Institute, Rome, Italy.
  • Umberto Anceschi
    Department of Urology, Regina Elena National Cancer Institute, Rome, Italy. Electronic address: umberto.anceschi@gmail.com.
  • Paolo Umari
    Division of Surgery and Interventional Sciences, University College London, London, UK.
  • Ashwin Sridhar
    Department of Urology and Division of Surgery and Interventional Science, University College London Hospital, London, UK.
  • John Kelly
    Department of Urology, University College London Hospital, London, UK.
  • Kees Hendricksen
    Department of Urology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
  • Sarah Einerhand
    Department of Urology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Noah Sandel
    Department of Urology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Rafael Sanchez-Salas
    Department of Urology, Institut Mutualiste Montsouris, Paris, France.
  • Anna Colomer
    Department of Urology, Institut Mutualiste Montsouris, Paris, France.
  • Thierry Quackels
    Department of Urology, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium.
  • Alexandre Peltier
    Department of Urology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
  • Francesco Montorsi
    Unit of Urology/Division of Oncology, Gianfranco Soldera Prostate Cancer Lab, URI, IRCCS San Raffaele Scientific Institute, Via Olgettina 58, 20132, Milan, Italy.
  • Alberto Briganti
    Unit of Urology/Division of Oncology, Gianfranco Soldera Prostate Cancer Lab, URI, IRCCS San Raffaele Scientific Institute, Via Olgettina 58, 20132, Milan, Italy.
  • Jeremy Y C Teoh
    The Chinese University of Hong Kong, Urology, Hong Kong, China.
  • Benjamin Pradere
    Department of Urology, University of Tours, Tours, France.
  • Marco Moschini
    Division of Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy.
  • Thierry Roumeguère
    Department of Urology, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium.